|Bid||32.00 x 1100|
|Ask||33.83 x 800|
|Day's Range||32.42 - 33.99|
|52 Week Range||18.66 - 73.90|
|Beta (3Y Monthly)||3.76|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 6, 2019 - Mar 11, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||66.69|
Biotech stocks like CRISPR Therapeutics (NASDAQ:CRSP) are inherently risky, and inherently volatile. CRISPR stock itself, only public for a little over two years, is a good example. CRSP stock went public at $14 — and cleared $70 this year.
The gene-editing pioneer reported third-quarter 2018 earnings and reported FDA acceptance of its first investigational new drug (IND) application.
The gene editor that pulled HIV from an unborn baby is this week's champ. Fed Chair Jerome Powell, backing down to critics, is the chump.
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $38.33, marking a -1.01% move from the previous day.
Crispr Therapeutics will launch a gene-editing therapy in the U.S. in 2022, an analyst predicted Friday as he initiated coverage with a buy rating.
A Chinese scientist from a university in Shenzhen claims he has succeeded in creating the world’s first genetically edited babies. We have no idea what effects the alteration of genes in sperm or ova or a fetus will have on future generations. CRISPRs evolved over millions of years to trim pieces of genetic information from one genome and insert it into another.
The researcher's claims, which have not yet been published in a scientific paper, prompted a swift outcry among Boston-area life sciences officials Monday, given that such genetic changes can be passed on to future generations.
ZUG, Switzerland and CAMBRIDGE, Mass., Nov. 21, 2018 -- CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines.
In November, among the ten analysts covering Editas Medicine (EDIT), six analysts recommended a “buy,” while four recommended a “hold.” The mean rating for Editas Medicine stock is 2.4 with a target price of $47.29, which implies an upside potential of 75.8% over Editas Medicine’s closing price of $26.9 on November 14.
NEW YORK, Nov. 13, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $36.17, moving -0.55% from the previous trading session.
CRISPR Therapeutics (CRSP) reported a net income of -$50.7 million in the third quarter—compared to a net income of -$24.7 million in the third quarter of 2017. CRISPR Therapeutics’ net income over the first nine months of 2018 was -$117.4 million—compared to -$68.5 million in the same period in 2017.
The future of genetic medicine — and DNA stocks — is extremely bullish over the long term. But as is normal of any emerging technology, there will be plenty of bumps along the road. The good news is that those bumps will provide many opportunities to buy DNA stocks along the way.
CRISPR Therapeutics (CRSP) reported revenues of $563,000 in the third quarter—compared to $2.4 million in the third quarter of 2017. CRISPR Therapeutics reported net revenues of $3.0 million over the first nine months of 2018—compared to $8.7 million during the same period in 2017. CRISPR Therapeutics’ net revenues are mainly from collaborations undertaken by the company.
On November 9, CRISPR Therapeutics’ (CRSP) stock price closed at $36.37, which is an ~3.53% decline from its close of $37.70 on November 8. On November 7, after the company reported its third-quarter financial results, the stock price grew ~10.81% to $38.85 from the close of $35.06 on November 6.
CRISPR Therapeutics (CRSP) and MaxCyte today announced the expansion of their existing relationship by entering into a non-exclusive commercial license agreement that will allow CRISPR Therapeutics to deploy MaxCyte’s Flow Electroporation® Technology to develop CRISPR/Cas9-based therapies in immuno-oncology. “As we advance our allogeneic CAR-T programs into the clinic, we are preparing for the future by securing our access to the leading ex vivo delivery platform for both clinical and commercial use, just as we previously did for our hemoglobinopathy developmental candidates,” said Samarth Kulkarni, CEO of CRISPR Therapeutics.
Editas Medicine could be the next to test the widely watched gene editing technology CRISPR/Cas9 after filing a clinical trial application late last month, the company revealed Wednesday.
-Initiated Phase 1/2 Clinical Trial of CTX001 in β-thalassemia- -Targeting Initiation of Clinical Trial for CTX110, Targeting CD19+ Malignancies, in 1H 2019--$487.3 Million in.
It was a busy month for gene editing stocks, which suffered from both CRISPR-specific news and the broader stock market's fall.